Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by stockman6767on Nov 22, 2016 8:16pm
198 Views
Post# 25499252

RE:RE:RE:Questions to Fred,

RE:RE:RE:Questions to Fred,thanx Bepando. I see where you are coming from. I am not sure but perhaps your assumption in #2 is problematic. Possibly the $7M spent to produce the Pg inventory included many other costs of production on top of the basic cost of plasma. I do not know the breakdown, but clearly if plasma cost is high, say over 90% of the cost then your calculation rings true, but if say the plasma cost is a small fraction of the overall cost of production say 10%-20% then your estimate will be way off.
Bullboard Posts